GlassScriptPhysician profile
Bryar A Bequette
NPI 1972161206
$8,121.37
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,189 · 2022: $2,495 · 2023: $3,312 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $89.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.81 |
| Education | $89.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.15 | 2021-2023 | |
| Janssen Biotech, INC. | $1,072.27 | 2021-2023 | Tremfya, Remicade, Simponi Aria |
| Pfizer INC. | $991.63 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $954.11 | 2021-2023 | |
| Amgen INC. | $736.76 | 2021-2024 | Enbrel, Tavneos, Avsola |
| Lilly USA, LLC | $722.90 | 2021-2023 | Taltz |
| Ucb, INC. | $608.65 | 2021-2024 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $184.41 | 2022-2023 | Saphnelo |
| Teva Pharmaceuticals USA, INC. | $156.15 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $119.72 | 2021-2023 | Orencia |
| Aurinia Pharma U.S., INC. | $113.36 | 2021-2023 | Lupkynis |
| Organon LLC | $106.23 | 2021-2023 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $89.90 | 2021-2023 | Nucala, Benlysta |
| Genzyme Corporation | $81.72 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.90 | 2021-2023 | Cyltezo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $76.61 | 2022-2023 | Krystexxa |
| Bioventus LLC | $69.80 | 2023 | Gelsyn-3 |
| Octapharma USA, INC. | $63.60 | 2022 | |
| Fresenius Kabi USA, LLC | $63.32 | 2023 | Idacio |
| Sandoz INC. | $63.05 | 2023 | Hyrimoz |
| Arbor Pharmaceuticals, INC. | $58.92 | 2021 | |
| Merck Sharp & Dohme LLC | $41.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.70 | 2023 | |
| Valinor Pharma, LLC | $37.63 | 2023 | Movantik |
| Genentech USA, INC. | $33.17 | 2021 | |
| Fidia Pharma USA INC. | $28.29 | 2021-2023 | Hymovis |
| Ferring Pharmaceuticals INC. | $24.14 | 2021-2022 | |
| Radius Health, INC. | $21.31 | 2021 | |
| Biocryst US Sales Co., LLC | $19.65 | 2021 | |
| Antares Pharma, INC. | $19.42 | 2021 | |
| Kyowa Kirin, INC. | $19.23 | 2023 | Crysvita |
| Virtus Pharmaceuticals LLC | $16.25 | 2021 | |
| Ani Pharmaceuticals, INC. | $15.49 | 2022 | |
| Celltrion USA INC. | $14.90 | 2023 | Yuflyma |
| Kowa Pharmaceuticals America, INC. | $14.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.40 | 2022 | |
| Eisai INC. | $12.72 | 2021 | |
| Medexus Pharma, INC. | $12.15 | 2021 | |
| Athena Bioscience, LLC | $7.44 | 2023 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryar Bequette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.